A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

NCT06969430 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Debio 1562M

Sponsor

Debiopharm International SA